Nalmefene: a new approach to the treatment of alcohol dependence [Corrigendum]

This article refers to:

Opioid-use disorder among patients on long-term opioid therapy: impact of final DSM-5 diagnostic criteria on prevalence and correlates

Paille F, Martini H. Substance Abuse and Rehabilitation 2014;5:87–94

On page 93, the Disclosure was listed as “The authors report no conflicts of interest in this work.”, however it should have been “Francois Paille is consultant for Ethypharm and Lundbeck, received honoraria from Ethypharm and Lundbeck, speaker fees from Lundbeck and Merck Serono and travel grants from Lundbeck. Hervé Martini received travel grants from Reckitt-Benckiser and Lundbeck.”